Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/13/25
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/12/25
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ETPRNewsWire • 02/05/25
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A BuySeeking Alpha • 01/23/25
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent CourtPRNewsWire • 01/13/25
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should KnowZacks Investment Research • 01/13/25
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CAPRNewsWire • 01/06/25
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?Zacks Investment Research • 12/19/24
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024PRNewsWire • 11/16/24
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance RaisedZacks Investment Research • 10/30/24